Although agents that directly target the PI3K/AKT/mTOR pathway have been shown to be ineffective in CRC [34], PIK3CA mutations have been implicated in EGFR-targeted therapy resistance, as well as increased benefit from aspirin treatment [35-38]. Here, AKT1 is linked to colorectal carcinoma.